Guidelines on the management of drug‐induced immune and secondary autoimmune, haemolytic anaemia

The objective of this guideline is to provide healthcare professionals with guidance on the management of patients with secondary autoimmune haemolytic anaemia (AIHA).The guidance may not be appropriate to every patient and in all cases, individual patient circumstances may dictate an alternative approach. MethodologyLiterature review details.Recommendations are based on the systematic review of published English language literature from January 1960 to October 2015 (see Appendix S1 for further details).Although recommendations are unchanged, an expanded version of this guideline is available as Appendix S2.The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and to assess the strength of recommendations.The GRADE criteria are specified in the British Committee for Standards in Haematology (BCSH) guidance pack (http://www.bcshguidances.com/BCSH_PROCESS/42_EVIDENCE_LEVELS_AND_GRADES_OF_RECOM MENDATION.html)and the GRADE working group website (http://www.gradeworkinggroup.org.Working group membership.The guideline group was selected to be representative of UK-based experts in the diagnosis and management of AIHA.Review.Review of the manuscript was performed by the BCSH General Haematology Task Force, BCSH Executive Committee and then a sounding board of the British Society for Haematology (BSH).This compromises 50 or more members of the BSH who have reviewed this Guidance and commented on its content and applicability in the UK setting.